Nippon Shinyaku has been granted a patent for an antisense oligomer designed to efficiently skip exon 44 of the human dystrophin gene. The oligomer comprises specific nucleotide sequences and includes modified nucleotides or morpholino structures, enhancing its therapeutic potential. GlobalData’s report on Nippon Shinyaku gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Nippon Shinyaku, Cancer treatment biomarkers was a key innovation area identified from patents. Nippon Shinyaku's grant share as of July 2024 was 46%. Grant share is based on the ratio of number of grants to total number of patents.
Antisense oligomer for exon skipping in dystrophin gene
The granted patent US12060556B2 outlines a novel antisense oligomer designed to induce skipping of exon 44 in the human dystrophin gene, which is significant for the treatment of muscular dystrophy. The claims specify that the antisense oligomer can be either an antisense oligonucleotide or a morpholino oligomer, with the former including modified nucleotides that feature alterations in the sugar moiety and/or phosphate-binding region. The patent details various modifications, such as the replacement of the 2'-OH group in ribose with different chemical groups, and identifies specific types of modified phosphate-binding regions, including phosphorothioate and phosphoramidate bonds.
Additionally, the patent encompasses pharmaceutical compositions that incorporate the antisense oligomer as an active ingredient, potentially combined with acceptable carriers for therapeutic use. Methods for administering these oligomers to patients with muscular dystrophy are also described, particularly targeting those with mutations amenable to exon 44 skipping. The claims emphasize the oligomer's application in human patients, thereby providing a framework for developing targeted therapies aimed at addressing the underlying genetic causes of muscular dystrophy.
To know more about GlobalData’s detailed insights on Nippon Shinyaku, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
